CYTOTEC (misoprostol) by Pfizer is clinical pharmacology pharmacokinetics misoprostol is extensively absorbed, and undergoes rapid de-esterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. Approved for postpartum hemorrhage, labor induction, cervical ripening. First approved in 1988.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CYTOTEC (misoprostol) is a prostaglandin E1 analog oral tablet approved in 1988 for prevention of NSAID-induced gastric ulcers and treatment of postpartum hemorrhage, labor induction, and cervical ripening. It works by binding to prostaglandin receptors to promote gastric mucosa protection and uterine contractions. The drug is indicated across obstetrics, rheumatology, and gastrointestinal protection, with significant off-label use globally.
Minimal commercial investment signals a legacy product in decline with limited team expansion; roles focus on compliance and managed care rather than growth.
CLINICAL PHARMACOLOGY Pharmacokinetics Misoprostol is extensively absorbed, and undergoes rapid de-esterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. The alpha side chain undergoes beta oxidation and the beta…
Worked on CYTOTEC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Prostaglandin E1 Analog
Comparison Between Vaginal Misoprostol Gel and Oral Misoprostol Solution in Induction of Labor
Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Comparison of Misoprostol Ripening Efficacy With Dilapan
REgistry of MisOprostol 200 µg Vaginal dElivery System
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCYTOTEC offers limited career growth potential given its LOE-approaching lifecycle and minimal linked job opportunities. Roles are defensive in nature, focused on maintaining market share and managing generic transition rather than driving innovation or expansion.